Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product
Receives First Milestone Payment for NXP001
Cambridge, UK, 27 November 2018: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has expanded its licensing agreement with Newsummit Biopharma (“NSB”), its Chinese licensing partner for NXP001, which is in development for cancer supportive care.
